This website is intended for healthcare professionals only.
CHALLENGES IN THE MANAGEMENT OF GI CANCER, A CLINICAL PERSPECTIVE ON 3L+ mCRC & mGC
Prof. Florian Lordick
MD, PhD
Director of the department of oncology, Leipzig University Medical Center, Germany
Prof. Pia Ă–sterlund
MD, PhD​
Adjunct professor of oncology, Karolinska Institutet, Sweden​
Deputy head of the Oncology Department, Tampere University Hospital, Finland
This webinar presents the differences and similarities between metastatic gastric cancer (mGC) and in metastatic colorectal cancer (mCRC) in terms of patients profiles, therapeutic objectives, and standard of care. It hightlights the need to increase the number of patients reaching 3L+ , and presents clinical results of approved 3L+ treatments for each condition. In addition, it emphasizes the importance of tailoring according to treatment goals. Two interactive clinical cases discuss 3L treatment choices and continuum of care in mGC and mCRC.
Key points covered
This webinar highlighted the challenges faced in treating mCRC and mGC patients, as well as therapeutic solutions depending on patients profiles.
Multi-professional management is essential
Tailoring according to treatment goals is a priority
Reaching 3L+ with maintained QoL is a reality for an increasing number of patients. In particular, RECOURSE and TAGS trials demonstrated FTD/TPI efficacy and safety in mCRC and mGC.
Webinar Replay
Featured Speakers
Professor Florian Lordick
Florian Lordick is the director of the UCCL. His scientific focus is on clinical and translational research in GI cancers. He is the ESMO director of education and president of the IGCA, as well as an associate editor of Gastric Cancer and ESMO Open, and editorial board member of Annals of Oncology.
Prof. Pia Ă–sterlund
Prof Pia Ă–sterlund is an Adjunct Professor and a Senior at Karolinska Institute and senior consultant at the Comprehensive Cancer Centre. She is also the Deputy Head of Oncology at Tampere university hospital and Head of the GI-cancer and tumor boards. She has been the PI in more than 30 clinical trials.
